A promising drug candidate for the treatment of glaucoma based on a P2Y6-receptor agonist
- 133 Downloads
Extracellular nucleotides can regulate the production/drainage of the aqueous humor via activation of P2 receptors, thus affecting the intraocular pressure (IOP). We evaluated 5-OMe-UDP(α-B), 1A, a potent P2Y6-receptor agonist, for reducing IOP and treating glaucoma. Cell viability in the presence of 1A was measured using [3-(4, 5-dimethyl-thiazol-2-yl) 2, 5-diphenyl-tetrazolium bromide] (MTT) assay in rabbit NPE ciliary non-pigmented and corneal epithelial cells, human retinoblastoma, and liver Huh7 cells. The effect of 1A on IOP was determined in acute glaucomatous rabbit hyaluronate model and phenol-induced chronic glaucomatous rabbit model. The origin of activity of 1A was investigated by generation of a homology model of hP2Y6-R and docking studies. 1A did not exert cytotoxic effects up to 100 mM vs. trusopt and timolol in MTT assay in ocular and liver cells. In normotensive rabbits, 100 μM 1A vs. xalatan, trusopt, and pilocarpine reduced IOP by 45 vs. 20–30%, respectively. In the phenol animal model, 1A (100 μM) showed reduction of IOP by 40 and 20%, following early and late administration, respectively. Docking results suggest that the high activity and selectivity of 1A is due to intramolecular interaction between Pα-BH3 and C5-OMe which positions 1A in a most favorable site inside the receptor. P2Y6-receptor agonist 1A effectively and safely reduces IOP in normotense, acute, and chronic glaucomatous rabbits, and hence may be suggested as a novel approach for the treatment of glaucoma.
KeywordsHuman P2Y6 receptor P2Y6 receptor agonist Glaucoma Intraocular pressure 5-OMe-uridine-5′-α-borano-diphosphate
[3-(4, 5-dimethyl-thiazol-2-yl) 2,5-diphenyl-tetrazolium bromide]
Human P2Y6 receptor
The authors gratefully acknowledge the support of the Office of the Israeli Chief Scientist, and Youdim Pharmaceuticals Ltd. Israel.
Compliance with ethical standards
Conflict of interest
Authors Orly Weinreb and Tali Fishman-Jacob received research grants from the Office of the Israeli Chief Scientist, and Youdim Pharmaceuticals Ltd. Israel.
This study does not contain any studies with human participants.
- 9.Shinozaki Y, Kashiwagi K, Namekata K, Takeda A, Ohno N, Robaye B, Harada T, Iwata T, Koizumi S (2017) Purinergic dysregulation causes hypertensive glaucoma–like optic neuropathy. JCI insight 2(19)Google Scholar
- 17.Zhang D, Gao ZG, Zhang K, Kiselev E, Crane S, Wang J, Paoletta S, Yi C, Ma L, Zhang W, Han GW, Liu H, Cherezov V, Katritch V, Jiang H, Stevens RC, Jacobson KA, Zhao Q, Wu B (2015) Two disparate ligand-binding sites in the human P2Y1 receptor. Nature 520(7547):317–321CrossRefPubMedPubMedCentralGoogle Scholar
- 22.Papadatos G, Overington JP (2014) The ChEMBL database: a taster for medicinal chemists. Future 6(4):361–364Google Scholar
- 24.Tjong Kim Sang EF, De Meulder F Introduction to the CoNLL-2003 shared task: language-independent named entity recognition. In: Proceedings of the seventh conference on Natural language learning at HLT-NAACL 2003-Volume 4, 2003. Association for Computational Linguistics, pp 142–147Google Scholar
- 31.Costanzi S, Joshi BV, Maddileti S, Mamedova L, Gonzalez-Moa MJ, Marquez VE, Harden TK, Jacobson KA (2005) Human P2Y6 receptor: molecular modeling leads to the rational design of a novel agonist based on a unique conformational preference. J Med Chem 48(26):8108–8111CrossRefPubMedPubMedCentralGoogle Scholar
- 34.Hillmann P, Ko G-Y, Spinrath A, Raulf A, von Kügelgen I, Wolff SC, Nicholas RA, Kostenis E, Höltje H-D, Müller CE (2009) Key determinants of nucleotide-activated G protein-coupled P2Y2 receptor function revealed by chemical and pharmacological experiments, mutagenesis and homology modeling. J Med Chem 52(9):2762–2775CrossRefPubMedGoogle Scholar
- 38.Azran S, Danino O, Förster D, Kenigsberg S, Reiser G, Dixit M, Singh V, Major DT, Fischer B (2015) Identification of highly promising antioxidants/neuroprotectants based on nucleoside 5′-phosphorothioate scaffold. Synthesis, activity, and mechanisms of action. J Med Chem 58(21):8427–8443CrossRefPubMedGoogle Scholar
- 39.Davson H (1993) The aqueous humour and the intraocular pressure, physiology of the eye. 5th Edn. Pergamon Press, New YorkGoogle Scholar
- 49.Carstairs J, Nimmo A, Barnes PJ (1985) Autoradiographic visualization of beta-adrenoceptor subtypes in human lung 1–3. Am Rev Respir Dis 132 (3):541–547Google Scholar